Health Care [ 11/12 ] | Biotechnology [ 66/74 ]
NASDAQ | Common Stock
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness.
It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.
It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings.
The company was incorporated in 2009 and is based in Norwood, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 6, 24 | -0.90 Increased by +56.10% | -1.19 Increased by +24.37% |
| May 7, 24 | -0.83 Increased by +80.42% | -1.09 Increased by +23.85% |
| Mar 12, 24 | -1.81 Increased by +30.65% | -2.36 Increased by +23.31% |
| Nov 7, 23 | -2.05 Increased by +2.38% | -2.06 Increased by +0.49% |
| Aug 8, 23 | -2.05 Increased by +37.88% | -3.10 Increased by +33.87% |
| May 9, 23 | -4.24 Decreased by -76.67% | -4.09 Decreased by -3.67% |
| Mar 7, 23 | -2.61 Decreased by -8.75% | -2.10 Decreased by -24.29% |
| Nov 8, 22 | -2.10 Decreased by -250.00% | -1.65 Decreased by -27.27% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 0.00 Decreased by N/A% | -10.00 M Decreased by -13.81% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -6.90 M Increased by +63.08% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 1.35 M Increased by +N/A% | -8.02 M Increased by +26.71% | Decreased by -594.27% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -10.05 M Decreased by -12.00% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -8.78 M Increased by +64.66% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -18.69 M Decreased by -68.60% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Increased by +100.00% | -10.94 M Decreased by -6.67% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by -100.00% | -8.98 M Decreased by -312.48% | Decreased by N/A% Decreased by N/A% |